Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “PLASMACYTOMA”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 1,225 records · Page 68Linked to original sources

Asymmetrical surface IgG on MOPC-21 plasmacytoma cells contains membrane heavy chain and one secretory heavy chain.

Membrane proteins from the B lymphomas WEHI-231 and 2PK3 and from the plasmacytomas MPC-11 and MOPC-21 were radioiodinated in situ by the lactoperoxidase method and were subjected to two-dimensional (nonreduced, reduced) polyacrylamide gel electrophoresis in the presence of sodium dodecyl sulfate. Few heavily labeled membrane proteins were composed of disulfide-bonded subunits. One such protein (m.w. 200,000 intact and 116,000 reduced) shared some properties with the PC-1 alloantigen, although it was not conclusively identified. A second major disulfide-bonded protein (m.w. 200,000 intact and 95,000 reduced) has been identified previously as the receptor for transferrin. Membrane immunoglobulins of WEHI-231 (IgM) and 2PK3 (IgG2a) had the expected subunit structure, whereas membrane immunoglobulin was not detected on MPC-11. In contrast, surface IgG1 of MOPC-21 appeared to consist almost entirely of hybrid molecules containing one membrane gamma 1 chain and one secretory gamma 1 chain. This hybrid IgG molecule appeared to exist in both monomeric and dimeric forms. It is concluded that i) the synthetic and assembly mechanisms of secretory and membrane IgG1 are shared; ii) there are no special mechanisms to prevent pairing of membrane and secretory gamma 1 chains; iii) the presence of one hydrophobic tail is sufficient for membrane insertion of gamma 1 chains; and iv) the C-terminal extension cysteine residues of membrane gamma 1 chains in hybrid IgG molecules are either unpaired or may allow the formation of hybrid IgG dimers.

Animals↗

Plasmacytoma of the thyroid gland.

Solitary plasmacytoma of the thyroid is very rare. Thus far, only 12 cases have been reported in literature. This report describes the clinical and histological features of two additional cases. One patient developed bone metastases 1 month after diagnosis and died 17 months later. The second patient is alive with no evidence of disease, 19 months after diagnosis. At the present time there are insufficient data to assess the prognosis in any single case.

Aged↗

Effect of a zinc-deficient diet on the growth of an IgM-secreting plasmacytoma (TEPC-183).

A diet deficient in zinc resulted in a significant decrease in the number of inbred BALB/c female mice developing transplantable plasmacytoma TEPC-183 compared to pair-fed and ad libitum-fed control mice. The size of the tumor relative to body weight was decreased in the zinc-deficient group. Whereas the uptake of [3H]thymidine into tumor cells did not differ between the groups, the incorporation of [3H]thymidine into tumor cells was significantly reduced in the animals maintained on a zinc-deficient diet.

Animals↗

Development of resistance to MOPC-315 plasmacytoma after intralesional and intraperitoneal melphalan therapy of tumor-bearing BALB/c mice. I. Enhancement of in vivo rejection responses by combined chemotherapy-immunotherapy.

Experimental and clinical evidence indicates that some chemotherapeutic agents may enhance tumor cell immunogenicity. This study was undertaken to test the possibility that melphalan [L-phenylalanine mustard (L-PAM)]--a clinically useful drug--can modulate tumor cells in vivo and in vitro in a syngeneic experimental system of MOPC-315 plasmacytoma in BALB/c mice and that this modulation can be expressed in vivo by enhanced tumor resistance. Tumor-bearing mice were treated with L-PAM intralesionally and ip by a split-course chemotherapy to avoid excessive toxicity of the drug. As a result of this treatment, about 60% of the mice had complete tumor regression; of these, 40-60% were resistant to viable tumor cell challenge and were designated as "cured-immune." Immunogenicity of irradiated MOPC-315 was tested in BALB/c mice; significant protection against tumor cell challenge was not achieved. In vitro L-PAM-treated MOPC-315 cells induced a measurable but weak antitumor response. Combination of both therapeutic approaches, i.e., chemotherapy and active immunization by L-PAM-treated tumor cells, was attempted with the use of various schedules. Immunotherapy given after L-PAM-induced tumor regression significantly enhanced in vivo antitumor response to challenge by 10(4) and 10(5) viable MOPC-315 tumor cells. When immunotherapy was attempted before chemotherapy in the presence of actively growing though still occult tumor, it reduced the chemotherapy cure rate and resulted in a low rate of tumor resistance. Addition of BCG did not remarkably affect the results. The findings point to the importance of timing of active immunization relative to tumor load and chemotherapy. The implication is that chemotherapy-induced regression is mediated by host immune mechanisms in this experimental model.

Animals↗

Metastatic properties conferred on nonmetastatic tumors by hybridization of spleen B-lymphocytes with plasmacytoma cells.

The P3-NSI/1-Ag4-1 (NSI) plasmacytoma, when transplanted sc in syngeneic BALB/c mice, grows locally without forming spontaneous metastases. We tested whether somatic hybridization of the NSI cells with spleen B-lymphocytes would render them metastatic in (C57BL/6 X BALB/c) F1 mice. We found that the hybridomas thus produced generated spontaneous metastases with distinct organ specificities. Some hybridomas produced metastases in both liver and spleen, whereas others produced metastases in only the liver. Cells derived from spleen-and liver-seeking hybridomas, when transplanted sc, produced tumors that metastasized to both the liver and spleen. Tumor cells derived from spleen metastasis produced, on transplantation, a tumor that generated spleen metastasis of a larger mass than did tumors derived from liver metastases. Cells derived from liver-seeking hybridomas metastasized to only the liver. Similar patterns of organ specificity were observed after iv injection of the hybridoma cells. The spleen seemed to play determining role in controlling the production of liver metastases by hybridomas that produced both liver and spleen metastases. Such hybridomas did not produce liver metastases when injected into splenectomized recipients. Hybridomas that were only liver-seeking did produce metastases in splenectomized recipients.

Animals↗

[Megaloblastic maturation disorder of erythropoiesis in plasmacytoma and chronic lymphatic leukemia].

Quantitative and qualitative investigations of the erythropoiesis in the sternal marrow of untreated 52 patients with a plasmacytoma and 46 patients with a chronic lymphatic leukaemia resulted in about half the cases in an indicated or more distinct megaloblastic disturbance of maturation in a part of the erythroblasts. These changes of the erythroblastic cells might be the expression of a neoplastic transformation and of a disturbance of the differentiation of the pluripotent stem cells in these diseases.

Aged↗

Development and characterization of a cyclophosphamide-resistant mouse plasmacytoma cell line.

Murine LPC-1 plasmacytoma is sensitive to treatment with cyclophosphamide (CY), and animals bearing this tumor in advanced stages can be cured with doses as small as 60 mg/kg. With repeated transfer of LPC-1 cells followed by subcurative CY therapy, we have developed from this CY-sensitive parent line (CY-S) a stable CY-resistant subline (CY-R) that is unaffected by doses as large as 250 mg/kg. Stability of this induced CY resistance in the absence of CY treatment has been demonstrated for greater than 14 transfer generations. The CY-R subline has been compared to the CY-S parent line and shown to be similar with respect to morphology, growth kinetics, survival time, synthesis of IgG 2a kappa M component, and DNA content and distribution. The CY-S parent line responds in vivo to CY analogs (ifosfamide and trofosfamide), as judged by decreased tumor mass and increased survival; the CY-R subline is resistant to the CY analogs. The response to carmustine (BCNU) was tested, and resistance to CY did not predict for response to this alkylating agent since the effect on both CY-S and CY-R lines was equal. The significance of the development of this CY-resistant subline and the implications for future research into the mechanisms of such resistance are discussed.

Animals↗

[Plasmoblastic and immunoblastic sarcoma. Differentiation of immunoglobulin-producing tumors (myeoloma multiplex, plasmacytoma)].

In the Department of the Pathology of the University of Pécs in 1953--1977 autopsy of 58 cases of myeloma multiplex (MM) and plasmacytoma (P) was performed and among them 4 cases of sarcoma was found. In the material of the Cytologic Center of the Academical Commission of Pécs two more cases of sarcoma occurred. According to the authors findings in the MM-autopsy material (I) in addition to the frequent "plasmocytic-plasmoblastic MM" in a few number (II) immunoblastic tumours could also be seen (immunoblastic MM). "Immunoblastic MM" disseminates more frequently (lymph nodes, spleen, kidney, liver) and the patients die earlier than in cases of "plasmocytic-plasmoblastic MM". Since sarcomatous changes appear to be polymorph and disseminated, for the reliable diagnosis examination of tissue specimens taken from several parts of the tumour is necessary. Recent data and the authors studies show, that immunoglobulin-producing tumours differ each other according to the degree of maturity of plasma cells

Autopsy↗

[Extramedullary plasmacytoma. Presentation of 3 cases].

The authors report three cases of extramedullary plasmacytoma, localized in the oral cavity, deltoid muscle and upper respiratory passages, respectively. The first case was followed for seven years until his death, the second case has been followed during nine years and is still alive and the third one is a recently diagnosed case.

Adenocarcinoma↗

[Apparently isolated plasmacytoma of bone. Clinical and prognostic data. 114 cases and review of literature (author's transl)].

The authors review 114 cases (including 18 personal cases) of apparently isolated plasmacytoma of bone (AIPB) followed-up for periods of a few weeks to 24 years. The number of patients still alive, without recurrence and/or extension to the bone marrow sharply dropped from 77% after 2 years to 15% after 10 years. At the time of diagnosis, AIPB with secondary medullary involvement differed from conventional multiple myeloma of bone on six points: mean age 52,1 versus 63,2 years (p less than 0,001); male prevalence 60,5% vs 38,5% (p less than 0,02); spinal involvement 61,8% vs 88,7% (p less than 0,05); radiological aspect of giant cell tumour 33,3% vs 3% (p less than 0,001); cord involvement 25% vs 5,4% (p less than 0,001); lack of monoclonal component 82,5% vs 4,3% (p less than 0,001). On the other hand, after 10 years there were only three differences between AIPB with and without secondary extension to the bone marrow: mean age 52,1 vs 45,7 years (p less than 0,1); spinal involvement 61,8% vs 26,7% (p less than 0,01); loss of monoclonal component after local treatment 29% vs 100% (p less than 0,05). These data suggest that isolated (i.e. localized) and multiple (i.e. disseminated) myelomas are distinct manifestations of bone marrow malignant plasma cell dyscrasias and that the patient's age, the site of the tumour and the disappearance of the monoclonal component are relevant to the prognosis of the disease.

Adult↗

Assessment of myeloma maintenance regimen of prednisone. Adriamycin, imuran, and vincristine in a murine plasmacytoma model.

A current southeastern cancer study group protocol for the treatment of multiple myeloma involves induction with BCNU, cyclophosphamide, and prednisone (BCP) and maintenance with either melphalan and prednisone (MP), prednisone, Adriamycin, imuran, and vincristine (PAIV), or delayed treatment of relapsed cases following induction. These combinations of drugs are used as induction regimens to establish their chemotherapeutic effects and hematological toxicity in the murine MOPC 104E plasmacytoma model. The three combinations of drugs produce rapid, reliable, and reproducible tumor regressions. However, MP is the only combination which consistently gives long-term disease-free survivors. This particular regimen has least toxicity and is considered to be most effective. BCP produces complete remission with no relapses; however, long-term survivors are not observed with this combination due to early deaths because of drug toxicity. Most of the mice on the PAIV regimen die due to drug toxicity. This combination is considered least effective. With the different drug regimens, toxic events and regressions are noted to occur at different time periods, indicating that perhaps tumor cells in different stages are being destroyed. Toxic events as measured by hematocrit and body weight changes always precede regression by several days. This disparity between rapid drug effects on the host and a delayed effect on the tumor remains unexplained but may possibly be used to advantage in designing future trials.

Animals↗

[Isolation, characterization, and translation of heterogeneous nuclear RNA from plasmacytoma cells].

It was found that during hot phenol fractionation of plasmacytoma MOPC-21 cells, which produce immunoglobulins of gamma 1 chi-type, separation of nuclear and nucleolar RNAs, differing in kinetics of accumulation of radioactive precursors, distribution during gradient centrifugation procedures and in base composition, takes place. D-RNA 63 degrees and D-RNA 85 degrees, which possess similar characteristics with D-RNAs, discovered earlier in other cells were isolated. It was stated, the D-RNA 85 degrees is considerably enriched by 3'-terminal poly(A) sequences in comparison with D-RNA 63 degrees. During translation in cell-free protein synthesising system from Xenopus oocytes, these two fractions of hnRNA induced formation of immunospecific products. D-RNA 85 degrees stimulated synthesis of gamma 1 and chi chains more efficiently, that D-RNA 63 degrees. Polyadenylated and non-adenylated both D-RNAs stimulated synthesis gamma 1 and chi chains of immunoglobulin G1 during translation. This fact indicates the absence of significant differences in the informational content. These results give opportunity to propose the existence of two levels of processing pre-mRNA for immunoglobulin chains.

Animals↗

[Solitary intracranial plasmacytoma : report of a case and review of the literature (author's transl)].

The authors report the case of a 71 year old woman affected by a solitary intracranial plasmacytoma. Computed tomography statement and monoclonal gammapathy found in the serum and in the cerebrospinal fluid permitted the diagnosis. Brain tumor and gammapathy improved after radiotherapy. A review of the 17 cases reported in the available literature showed some characteristics of these tumors : epidemiology, localization, evolution.

Aged↗

Immunosuppression in BALB/c mice bearing the plasmacytoma TEPC-183: massive increase in red pulp macrophages induced by the tumour.

An increase was found in total macrophage numbers in the spleens of BALB/c mice bearing the plasmacytoma TEPC-183 compared with controls. The increase was shown to be confined to red pulp macrophage; white pulp macrophage numbers were normal as were the number of macrophages which took up hydroxyethyl starch. It is suggested that this increase in red pulp macrophages may account for the suppression of primary immune responses caused by spleen cells from TEPC-183 bearing mice. This effect may be due to increased numbers of normal macrophages rather than the generation of distinctive suppressor macrophages as suggested previously.

Animals↗

Effect of cyclophosphamide on the immune response of BALB/c mice bearing an immunoglobulin M plasmacytoma (TEPC-183).

Mice bearing TEPC-183, an immunoglobulin (M(kappa)-secreting plasmacytoma, exhibit severe suppression of their immune responses. Since chemotherapy with cyclophosphamide (CY) is used in the treatment of myeloma, the present study was undertaken to determine its effect on the immune response. CY was tested at different doses in order to establish whether a tumor-lytic dose could be established which would minimally impair the immune response. In addition, CY was injected at different time intervals in respect to antigen administration, and its short- and long-term effects on the immune response were determined. It was found that 1 mg CY suppressed the six-day primary immune response to the type 3 pneumococcal polysaccharide SSS-III, and even a secondary response 30 days later. Three mg CY were required to suppress the primary as well as the secondary immune response elicited by 2,4-dinitrophenyl-hemocyanin. One injection of 1 mg CY per mouse resulted in complete regression of all tumors. Splenectomy did not aid in the recovery of the immune response to SSS-III but accentuated the impairment. The time of CY administration played a crucial role in affecting the immune response. When CY was administered simultaneously with or two days after antigen injection, it was totally suppressive, whereas the immune response was enhanced when CY was given four days prior to antigen injection. Minimal effects were observed when CY was given at other time intervals.

Animals↗

Tumor immunity to murine plasma cell tumours. Influence of responder genotype on the specificity of the immune response to plasmacytomas and T lymphomas.

A tumour-associated antigen has been identified which is expressed on both BALB/c plasmacytomas and T lymphomas, but which does not induce a detectable cell-mediated immune response in the strain of origin of the tumours. The (BALB/c x C57BL) F1 hybrid, however, makes a readily detectable response both in vivo and in vitro in vitro experiments with various BALB/c H-2 F1 cogenic mice indicated that the genetic control of the response was not H-2 linked, and was associated with other C57BL genes.

Animals↗

Hepatic plasmacytoma and biclonal gammopathy in a cat.

A 13-year-old castrated male domestic shorthair cat was evaluated because of weight loss, despite a good appetite. The most remarkable abnormality was a total serum protein concentration of 12.4 g/dl, with a globulin concentration of 9.4 g/dl. Serum protein electrophoresis revealed a biclonal spike in the gamma region. At necropsy, 2 discrete plasmacytomas were found in the liver, without bone marrow involvement or amyloidosis.

Animals↗